Pre- And postexposure use of human monoclonal antibody against H5N1 and H1N1 influenza virus in mice: Viable alternative to oseltamivir

Journal of Infectious Diseases

Volumn 200, Issue 12, 2009, Pages 1870-1873

  Koudstaal, Wouter ^a   Koldijk, Martin H ^a   Brakenhoff, Just P J ^a   Cornelissen, Lisette A H M ^b   Weverling, Gerrit Jan ^a   Friesen, Robert H E ^a   Goudsmit, Jaap ^a  

^a CRUCELL HOLLAND BV   (Netherlands)

^b WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CR 6261; MONOCLONAL ANTIBODY; OSELTAMIVIR; UNCLASSIFIED DRUG; ZANAMIVIR;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; INFECTION PREVENTION; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY DISTRESS; SINGLE DRUG DOSE; TREATMENT OUTCOME; VIRUS NEUTRALIZATION; WEIGHT REDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; BODY WEIGHT; FEMALE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 71949127249     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/648378     Document Type: Article

References (14)

1. World Health Organization (WHO). Fact sheet 211: influenza. Geneva: World Health Organization, 2003.
2. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2006; 55:1-42.
3. Moscona A. Medical management of influenza infection. Annu Rev Med 2008; 59:397-413.
4. Stephenson I, Democratis J, Lackenby A, et al. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin Infect Dis 2009; 48:389-396
5. World Health Organization. Influenza A(H1N1) virus resistance to oseltamivir-2008/2009 influenza season. Geneva: World Health Organization, 2009.
6. Poland GA, Jacobson RM, Ovsyannikova IG. Influenza virus resistance to antiviral agents: a plea for rational use. Clin Infect Dis 2009; 48: 1254-1256
7. Ekiert DC, Bhabha G, Elsliger MA, et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009; 324:246-251
8. Throsby M, van den Brink E, Jongeneelen M, et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS ONE 2008; 3:e3942.
9. ter Meulen J, Bakker AB, van den Brink EN, et al. Human monoclonal antibody as prophylaxis for SARS Coronavirus infection in ferrets. Lancet 2004; 363:2139-2141
10. 10. Subbarao K, Klimov A, Katz J, et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 1998; 279:393-396 (Pubitemid 28063376)
11. Sidwell RW, Bailey KW, Bemis PA, Wong MH, Eisenberg EJ, Huffman JH. Influence of treatment schedule and viral challenge dose on the in vivo influenza virus-inhibitory effects of the orally administered neuraminidase inhibitor GS 4104. Antivir Chem Chemother 1999; 10: 187-193
12. 12. Govorkova EA, Leneva IA, Goloubeva OG, Bush K, Webster RG. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother 2001; 45:2723-2732 (Pubitemid 32906663)
13. Leneva IA, Roberts N, Govorkova EA, Goloubeva OG, Webster RG. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/ 99 (H9N2) influenza viruses. Antiviral Res 2000; 48:101-115
14. Bakker AB, Python C, Kissling CJ, et al. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine 2008; 26:5922-5927